SCHEDULE: Squadron Master Fund Discloses Traws Pharma Stake

Squadron Master Fund LP, along with affiliated entities and individuals, has reported beneficial ownership of 511,714 shares, representing 6.4% of Traws Pharma, Inc.'s common stock.

Summary

• Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank have collectively reported beneficial ownership of 511,714 shares of Traws Pharma, Inc. common stock.
• This holding represents 6.4% of the total outstanding shares, based on 7,990,867 shares as of November 10, 2025.
• Squadron Capital Management, LLC acts as the investment adviser to Squadron Master Fund LP and other private funds.
• Matthew Sesterhenn and William Blank, as Partners of Squadron Capital Management, LLC, may be deemed beneficial owners due to their investment and voting discretion.
• All parties expressly disclaim beneficial ownership, stating the filing is not an admission of such ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an investment fund and its affiliates, without any indication of new strategic moves or financial performance.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

• Squadron Capital Management, LLC, which serves as investment adviser to private funds, including but not limited to Squadron Master Fund LP (collectively, the "Funds"), may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds.
• Mr. Sesterhenn and Mr. Blank, as Partners of Squadron Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds.
• Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Squadron Capital Management, LLC and Mr. Sesterhenn and Mr. Blank expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Squadron Capital Management, LLC or Mr. Sesterhenn and Mr. Blank are the beneficial owner of any of the securities reported herein.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing indicates a significant institutional investor's stake in Traws Pharma, Inc., which is typical for companies in the biotechnology or pharmaceutical sectors where substantial capital and long-term investment horizons are often required.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant ownership, which can influence market perception and trading activity.

Key Dates

Keywords

Schedule 13G, Traws Pharma, Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, William Blank, Beneficial Ownership, Common Stock, SEC Filing